New data shows benefit of drug combination for metastatic castration resistant prostate cancer

New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer (mCRPC).

Generated by Feedzy